SCHEMBL25254096

SCHEMBL25254096

Cc1ccc(-c2ccc3c(c2)C(=O)NS(=O)(=O)N3)c(Cl)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE7A Q13946 1/20 0.43
▸ PDE7B Q9NP56 1/20 0.43
▸ ROS1 P08922 1/20 0.39
▸ CDK5 Q00535 1/20 0.39
▸ ACVR1 Q04771 1/20 0.39
▸ LRRK2 Q5S007 1/20 0.39
▸ ALDH1A1 P00352 2/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ ALKBH3 Q96Q83 1/20 0.36
▸ CA12 O43570 2/20 0.35
▸ CA2 P00918 2/20 0.35
▸ CA7 P43166 2/20 0.35
▸ CA9 Q16790 2/20 0.35
▸ CA1 P00915 1/20 0.35
▸ CA4 P22748 1/20 0.35
▸ CSNK1G1 Q9HCP0 1/20 0.35
▸ TNKS2 Q9H2K2 3/20 0.34
▸ CES1 P23141 1/20 0.34
▸ CDC7 O00311 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12745929 0.80 RET (0.55) CDK5ACVR1LRRK2ALDH1A1KDM4E
SCHEMBL28928126 0.77 ROS1 (0.40) ROS1CDK5ACVR1LRRK2ALDH1A1
SCHEMBL23952183 0.75 ROS1 (0.38) ROS1CDK5ACVR1LRRK2ALDH1A1
SCHEMBL23952185 0.73 THRB (0.34) ALDH1A1KDM4EHSD17B10FFAR1
SCHEMBL23951911 0.69 PDE4A (0.54) PDE7APDE7BALDH1A1KDM4ECA12
SCHEMBL30110698 0.69 PDE4A (0.54) PDE7APDE7BALDH1A1KDM4ECA12
SCHEMBL12745931 0.69 RET (0.55) CDK5ACVR1LRRK2ALDH1A1KDM4E
SCHEMBL12746150 0.69 VEGFA (0.40) ALKBH3TNKS2FFAR1PGRNPC1
SCHEMBL23951943 0.68 TNKS2 (0.41) LRRK2ALDH1A1KDM4ETNKS2NPC1
SCHEMBL19323001 0.68 HPGD (0.45) ALDH1A1KDM4EHSD17B10ALKBH3NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219913-A1 Sulfamoylamide Derivatives HOFFMANN-LA ROCHE INC. (US) 2023-07-13 — — US claimed
CN-115427402-A Sulfamide derivatives 豪夫迈·罗氏有限公司 2022-12-02 — — CN claimed
US-20230219913-A1 Sulfamoylamide Derivatives HOFFMANN-LA ROCHE INC. (US) 2023-07-13 — — US disclosed
US-20230219913-A1 Sulfamoylamide Derivatives HOFFMANN-LA ROCHE INC. (US) 2023-07-13 — — US disclosed
EP-4136081-A1 SULFAMOYLAMIDE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2023-02-22 — — EP disclosed
CN-115427402-A Sulfamide derivatives 豪夫迈·罗氏有限公司 2022-12-02 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219913-A1 Sulfamoylamide Derivatives SULT2A1, SULT1A1, SPTLC3 PDE7A 4591/4885PDE7B 4352/4885ROS1 3952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback